Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P06744

UPID:
G6PI_HUMAN

ALTERNATIVE NAMES:
Autocrine motility factor; Neuroleukin; Phosphoglucose isomerase; Phosphohexose isomerase; Sperm antigen 36

ALTERNATIVE UPACC:
P06744; B4DG39; Q9BRD3; Q9BSK5; Q9UHE6

BACKGROUND:
The enzyme Glucose-6-phosphate isomerase, also recognized as Phosphoglucose isomerase and Sperm antigen 36 among other names, is integral to both glycolysis and gluconeogenesis. It also functions as a secreted cytokine, facilitating endothelial cell motility, acting as a neurotrophic factor, and inducing immunoglobulin secretion, showcasing its diverse biological roles.

THERAPEUTIC SIGNIFICANCE:
Its association with Hemolytic anemia, non-spherocytic, due to glucose phosphate isomerase deficiency, underscores the enzyme's importance in human health. Exploring Glucose-6-phosphate isomerase's roles could open doors to potential therapeutic strategies for treating a range of diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.